SINDROM NERVOZNIH CREVA KOD DECE – KAKO DO DIJAGNOZE
DOI:
https://doi.org/10.46793/PP180319005RKljučne reči:
Irritable bowel syndrome, deca, patogeneza, dijagnoza, Rome ktiterijumiApstrakt
Sindrom iritabilnog creva (IBS) je hronični i recidivni funkcionalni gastrointestinalni poremećaj. IBS obuhvata 9% -23% svetske populacije. Epidemiološke studije kod populacije mlađe od 18 godina ukazuju na veću prevalenciju među tinejdžerima i decom u poređenju sa odraslom populacijom. Patofiziologija IBS-a još nije u potpunosti jasna i izgleda da je multifaktorna. Mnogi patogenetski faktori, u različitim kombinacijama, i ne svi obavezno prisutni kod svakog pacijenta, mogu igrati važnu ulogu. Nelagodnost ili bol u trbuhu koji nestaju defekacijom, udruženi sa promenama oblika stolice, tipična je klinička manifestacija IBS-a. Mnogi faktori, kao što su emocionalni stres i neka hrana, mogu započeti i pogoršati simptome. Pravovremena dijagnoza IBS je važna da bi se primenio tretman koji će obezbediti adekvatno simptomatsko olakšanje (bol i nelagodnost, dijareja, konstipacija). Ne postoje specifični testovi za dijagnozu IBS. Dijagnoza se postavlja korišćenjem kriterijuma zasnovanih na kliničkim simptomima kao što su Roma kriterijumi. Danas su Roma IV kriterijumi zlatni standard za dijagnozu IBS-a kod adultne i dečije populacije. Lečenje bolesnika sa IBS-om zahteva multidisciplinarni pristup. Neki pacijenti dobro reaguju na ne-farmakološki tretman, dok drugi zahtevaju farmakološki tretman.
Reference
Sinagra E, Romano C, Cottone M. Psychopharmacological treatment and psychological interventions in irritable bowel syndrome. Gastroenterol Res Pract 2012;2012:486067.
Belcaro G, Gizzi G, Pellegrini L, Corsi M, Dugall M, Cacchio M, et al. Supplementation with a lecithin-based delivery form of Boswellia serrata extract (Casperome®) controls symptoms of mild irritable bowel syndrome. Eur Rev Med Pharmacol Sci. 2017;21(9):2249-2254.
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.
Soares RL. Irritable bowel syndrome: A clinical review. World J Gastroenterol. 2014;20(34):12144-60.
Noddin L, Callahan M, Lacy BE. Irritable bowel syndrome and functional dyspepsia: different diseases or a single disorder with different manifestations? MedGenMed. 2005;7(3):17.
Scalera A, Loguercio C. Focus on irritable bowel syndrome. Eur Rev Med Pharmacol. Sci 2012;16(9):1155-71.
Saha L. Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine.World J Gastroenterol. 2014;20(22):6759-6773.
Canavan C, West J, Card T. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 2014;6:71-80.
Grundmann O, Yoon SL. Irritable bowel syndrome: Epidemiology, diagnosis and treatment: An update for healthcare practitioners. J Gastroenterol Hepatology. 2010 ;25(4):691-699.
National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [internet]. London: National Institute for Health and Care Excellence (NICE); 2015.
Karabulut GS, Beşer OF, Erginöz E, Kutlu T, Cokuğraş FÇ, Erkan T. The Incidence of Irritable Bowel Syndrome in Children Using the Rome III Criteria and the Effect of Trimebutine Treatment. J Neurogastroenterol Motil. 2013;19(1):90-3. doi: 10.5056/jnm.2013.19.1.90.
Rajindrajith S, Devanarayana NM. Subtypes and Symptomatology of Irritable Bowel Syndrome in Children and Adolescents: A School-based Survey Using Rome III Criteria. J Neurogastroenterol Motil. 2012;18(3):298-304.doi: 10.5056/jnm.2012.18.3.298.
McOmber ME, Shulman RJ. Recurrent Abdominal Pain and Irritable Bowel Syndrome in Children. Current opinion in pediatrics.2007;19(5):581-585. doi:10.1097/MOP.0b013e3282bf6ddc.
Zhou H, Li D, Cheng G, Fan J, Lu H. An epidemiologic study of irritable bowel syndrome in adolescents and children in South China: a school-based study. Child Care Health Dev. 2010;36(6):781-6. doi: 10.1111/j.1365-2214.2010.01120.x.
Zhu X, Chen W, Zhu X, Shen Y. A cross-sectional study of risk factors for irritable bowel syndrome in children 8-13 years of age in suzhou, china. Gastroenterol Res Pract. 2014;2014:198461. doi: 10.1155/2014/198461
Lovell RM, Ford AC. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 2012;10(7):712-721.
Mohammed I, Cherkas LF, Riley SA, Spector TD, Trudgill NJ. Genetic influences in irritable bowel syndrome: a twin study. Am J Gastroenterol. 2005;100(6):1340-4.
Bellini M, Gambaccini D, Stasi C, Urbano MT, Marchi S, Usai-Satta P. Irritable bowel syndrome: A disease still searching for pathogenesis, diagnosis and therapy. World J Gastroenterol. 2014;20(27):8807-8820.
Chumpitazi BP, Shulman RJ. Underlying molecular and cellular mechanisms in childhood irritable bowel syndrome. Molecular and Cellular Pediatrics. 2016;3:11.
Drossman DA. Functional gastrointestinal disorders: history, pathophysiology, clinical features and Rome IV. Gastroenterology. 2016;150:1262-1279.
Posserud I, Ersryd A, Simrén M. Functional findings in irritable bowel syndrome. World J Gastroenterol. 2006;12(18):2830-8.
Dorn SD, Palsson OS, Thiwan SI, Kanazawa M, Clark WC, van Tilburg MA, et al. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an increased tendency to report pain rather than increased neurosensory sensitivity. Gut. 2007;56(9):1202-9.
Benninga MA, Faure C, HymanPE, et al. Childhood functional gastrointestinal disorders: neonate/toddler. Gastroenterology. 2016;150(6):1443–1455.e2.
Hyland NP, Quigley EM, Brint E. Microbiota-host interactions in irritable bowel syndrome: Epithelial barrier, immune regulation and brain-gut interactions.World Journal of Gastroenterology: WJG. 2014;20(27):8859-8866.
Atkinson W, Sheldon TA, Shaath N, Whorwell PJ. Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial. Gut. 2004;53(10):1459-64.
Elli L, Branchi F, Tomba C, Villalta D, Norsa L, Ferretti F, et al. Diagnosis of gluten related disorders: Celiac disease, wheat allergy and non-celiac gluten sensitivity. World Journal of Gastroenterology: WJG .2015;21(23):7110-7119.
Seo AY, Kim N, Oh DH. Abdominal Bloating: Pathophysiology and Treatment.Journal of Neurogastroenterology and Motility. 2013;19(4):433-453.
Sunderland R. Irritable bowel syndrome in adults: symptoms, treatment and management. Nurs Stand. 2017;31(26):52-63.
Koppen IJ, Nurko S, Saps M, Di Lorenzo C, Benninga MA.The pediatric Rome IV criteria: what's new? Expert Rev Gastroenterol Hepatol. 2017;11(3):193-201. doi: 10.1080/17474124.2017.1282820. Schmulson MJ, Drossman DA. What Is New in Rome IV. Neurogastroenterol Motil. 2017;23(2):151-163.
Simren M, Palsson OS, Whitehead WE. Update on Rome IV Criteria for Colorectal Disorders: Implications for Clinical Practice. Curr Gastroenterol Rep. 2017;19(4):15.
Drossman DA, Thompson WG, Talley NJ, Funch-Jensen P, Janssens J, Whitehead WE. Identification of subgroups of functional bowel disorders. Gastroenterology International. 1990;3(4):159-172.
